Stock A128940 HANMI PHARM. CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Hanmi Pharm. Co., Ltd.

Equities

A128940

KR7128940004

Pharmaceuticals

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
310,500 KRW +0.16% Intraday chart for Hanmi Pharm. Co., Ltd. +0.65% -11.91%
Mar. 19 Hanmi Pharm. Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Jan. 31 Aptose Biosciences Inc. announced that it has received $4 million in funding from Hanmi Pharm. Co., Ltd. CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 3,490,741 4,397,245 3,373,870 3,711,167 4,473,421 4,041,166 - -
Enterprise Value (EV) 2 4,184 5,040 3,855 4,231 4,473 4,224 4,032 4,041
P/E ratio 65.7 x 368 x 50.3 x 36.5 x 30.6 x 25 x 21.2 x 17.4 x
Yield 0.17% 0.14% 0.18% 0.17% - 0.16% 0.16% 0.16%
Capitalization / Revenue 3.13 x 4.09 x 2.8 x 2.79 x 3 x 2.48 x 2.3 x 2.58 x
EV / Revenue 3.76 x 4.68 x 3.2 x 3.18 x 3 x 2.6 x 2.29 x 2.58 x
EV / EBITDA 26.3 x 45.7 x 18 x 16.6 x 14 x 12.6 x 11.2 x 10.2 x
EV / FCF -27.2 x 45.9 x 21.2 x 32.1 x - 23.1 x 19.8 x 18.4 x
FCF Yield -3.67% 2.18% 4.72% 3.12% - 4.32% 5.06% 5.44%
Price to Book 4.73 x 6.02 x 4.2 x 4.26 x - 3.56 x 3.05 x 2.76 x
Nbr of stocks (in thousands) 12,744 12,732 12,718 12,703 12,691 12,688 - -
Reference price 3 273,920 345,361 265,283 292,157 352,500 310,500 310,500 310,500
Announcement Date 2/7/20 2/4/21 1/27/22 2/8/23 2/2/24 - - -
1KRW in Million2KRW in Billions3KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 1,114 1,076 1,206 1,332 1,491 1,627 1,759 1,569
EBITDA 1 159.3 110.3 214.5 254.9 319.1 335.3 361.3 394.4
EBIT 1 103.9 48.68 127.4 157 220.7 237.7 268.9 315.3
Operating Margin 9.33% 4.52% 10.56% 11.79% 14.8% 14.61% 15.28% 20.1%
Earnings before Tax (EBT) 1 83.3 22.13 103.8 116.9 194 220.6 255.3 308.2
Net income 1 52.11 11.96 81.08 76.93 159.3 159.3 183.2 228.4
Net margin 4.68% 1.11% 6.72% 5.78% 10.68% 9.79% 10.42% 14.55%
EPS 2 4,170 939.5 5,270 7,994 11,522 12,411 14,639 17,824
Free Cash Flow 3 -153,685 109,719 181,974 131,890 - 182,504 203,851 219,925
FCF margin -13,800.71% 10,198.36% 15,088.37% 9,903.76% - 11,219.26% 11,588.6% 14,015.85%
FCF Conversion (EBITDA) - 99,459.77% 84,835.58% 51,735.49% - 54,434.34% 56,424.52% 55,758.38%
FCF Conversion (Net income) - 917,443.51% 224,446.95% 171,451.1% - 114,567.95% 111,261.86% 96,299.95%
Dividend per Share 2 461.9 471.2 480.6 490.2 - 492.6 500.5 502.0
Announcement Date 2/7/20 2/4/21 1/27/22 2/8/23 2/2/24 - - -
1KRW in Billions2KRW3KRW in Million
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 303.1 350.5 321.1 316.5 342.1 351.3 361.7 342.7 364.6 422.4 398.5 382.8 399.6 444.3 414
EBITDA 1 - - - 54.47 72.67 64.1 84.57 57.83 - 94.72 94.8 74.1 85.6 74.3 -
EBIT 1 36.88 42.72 38.67 29.57 46.8 37.76 60.45 33.16 57.52 70.1 66.01 47.34 58.47 67.14 76
Operating Margin 12.17% 12.19% 12.04% 9.34% 13.68% 10.75% 16.71% 9.67% 15.78% 16.6% 16.57% 12.37% 14.63% 15.11% 18.36%
Earnings before Tax (EBT) 1 32.12 34.14 35.67 26.41 37.89 16.6 55.62 25.43 56.28 56.91 68.6 41.85 60.7 56.65 83
Net income 1 23.4 17.47 19.31 18.02 25.37 13.61 43.11 16.06 54.71 47.45 48.82 29.45 45.3 30.75 -
Net margin 7.72% 4.98% 6.01% 5.69% 7.42% 3.87% 11.92% 4.68% 15% 11.23% 12.25% 7.69% 11.34% 6.92% -
EPS - - - - - - - - - - - - - - -
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 11/4/21 1/27/22 4/27/22 7/18/22 11/1/22 2/8/23 4/26/23 7/28/23 11/1/23 2/2/24 - - - - -
1KRW in Billions
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 693 643 481 519 - 182 - -
Net Cash position 1 - - - - - - 9.3 -
Leverage (Debt/EBITDA) 4.354 x 5.825 x 2.244 x 2.038 x - 0.5443 x - -
Free Cash Flow 2 -153,685 109,719 181,974 131,890 - 182,504 203,851 219,925
ROE (net income / shareholders' equity) 7.93% 1.65% 9.21% 9.89% 15.1% 14.9% 14.8% 17.2%
ROA (Net income/ Total Assets) 3.54% 0.63% 3.51% 4.29% - 8.3% 9.1% 10.1%
Assets 1 1,471 1,898 2,310 1,794 - 1,919 2,014 2,256
Book Value Per Share 3 57,930 57,329 63,128 68,632 - 87,201 101,960 112,454
Cash Flow per Share 3 996.0 11,901 15,876 12,773 - 22,378 24,114 29,363
Capex 1 166 41.8 19.9 30.4 - 50.8 63.1 52.4
Capex / Sales 14.92% 3.89% 1.65% 2.28% - 3.13% 3.58% 3.34%
Announcement Date 2/7/20 2/4/21 1/27/22 2/8/23 2/2/24 - - -
1KRW in Billions2KRW in Million3KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Hanmi Pharm. Co., Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
310,500 KRW
Average target price
408,486 KRW
Spread / Average Target
+31.56%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

1st Jan change Capi.
HANMI PHARM. CO., LTD. Stock Hanmi Pharm. Co., Ltd.
-11.91% 2.86B
SUN PHARMACEUTICAL INDUSTRIES LTD. Stock Sun Pharmaceutical Industries Ltd.
+20.81% 43.34B
OTSUKA HOLDINGS CO., LTD. Stock Otsuka Holdings Co., Ltd.
+20.44% 21.96B
SANDOZ GROUP AG Stock Sandoz Group AG
+12.23% 14.09B
CIPLA LIMITED Stock Cipla Limited
+12.97% 13.64B
ZYDUS LIFESCIENCES LIMITED Stock Zydus Lifesciences Limited
+39.74% 11.43B
ONO PHARMACEUTICAL CO., LTD. Stock Ono Pharmaceutical Co., Ltd.
-8.59% 6.86B
THE MEDICINES COMPANY Stock The Medicines Company
-0.05% 6.79B
STADA ARZNEIMITTEL Stock STADA Arzneimittel
-8.87% 5.73B
ASPEN PHARMACARE HOLDINGS LIMITED Stock Aspen Pharmacare Holdings Limited
+8.46% 5.22B
Generic Pharmaceuticals
  1. Stock Market
  2. Equities
  3. A128940 Stock
  4. Financials Hanmi Pharm. Co., Ltd.